Second-generation antidepressant
| Second-generation antidepressant | |
|---|---|
| Drug class | |
| Class identifiers | |
| Use | Depressive disorders |
| External links | |
| MeSH | D018687 |
| Legal status | |
| In Wikidata | |
The second-generation antidepressants are a class of antidepressants characterized primarily by the era of their introduction, approximately coinciding with the 1970s and 1980s, rather than by their chemical structure or by their pharmacological effect. As a consequence, there is some controversy over which treatments actually belong in this class.
The term "third generation antidepressant" is sometimes used to refer to newer antidepressants,[1] from the 1990s and 2000s, often selective serotonin reuptake inhibitors (SSRIs) such as; fluoxetine (Prozac), paroxetine (Paxil) and sertraline (Zoloft), as well as some non-SSRI antidepressants such as mirtazapine, nefazodone, venlafaxine, duloxetine and reboxetine. However, this usage is not universal.
- ^ Olver JS, Burrows GD, Norman TR (2001). "Third-generation antidepressants: do they offer advantages over the SSRIs?". CNS Drugs. 15 (12): 941–54. doi:10.2165/00023210-200115120-00004. PMID 11735614. S2CID 39029287.